Trial Profile

A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Picankibart (Primary)
Indications Plaque psoriasis
Focus Therapeutic Use
Sponsors Innovent Biologics

Most Recent Events

27 Apr 2025 Status changed from active, no longer recruiting to completed.
28 Oct 2024 According to Innovent Biologics Media Release, Results from this study will provide evidence for novel long-term treatment regimens for patients with moderate to severe psoriasis and company will advance the Phase 3 clinical trial of picankibart.
28 Oct 2024 Results presented in the Innovent Biologics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com